Powered by: Motilal Oswal
2026-09-08 02:36:40 pm | Source: Accord Fintech
Neuland Lab surges as its Board approves Rs 126 crore capex
Neuland Lab surges as its Board approves Rs 126 crore capex

Neuland Laboratories is currently trading at Rs. 23661.70, up by 789.35 points or 3.45% from its previous closing of Rs. 22872.35 on the BSE.

The scrip opened at Rs. 23000.00 and has touched a high and low of Rs. 23,947.15 and Rs. 23000.00 respectively. So far 2784 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 23,947.15 on 8-Sept-2026 and a 52 week low of Rs. 11500.00 on 23-Mar-2026.

Last one week high and low of the scrip stood at Rs. 23,947.15 and Rs. 22390.60 respectively. The current market cap of the company is Rs. 30468.42 crore.

The promoters holding in the company stood at 32.62%, while Institutions and Non-Institutions held 37.59% and 29.79% respectively.

Neuland Laboratories’ Board has approved capital expenditure (capex) of Rs 126 crore towards the purchase of around 134 acres of land situated at Auro Industrial City, Kakinada, Andhra Pradesh, including other related expenditure.

The company also has a right of first refusal to purchase an additional contiguous land parcel of around 66 acres at a later date, taking the potential aggregate land parcel at the said location to around 200 acres. The capital expenditure will be funded through internal accruals.

Disclaimer: The content of this article is for informational purposes only and should not be considered financial or investment advice. Investments in financial markets are subject to market risks, and past performance is not indicative of future results. Readers are strongly advised to consult a licensed financial expert or advisor for tailored advice before making any investment decisions. The data and information presented in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the content of this article for any current or future financial references. To Read Complete Disclaimer Click Here